Mumbai, February 21, 2018: Pharma major, Suven Life Sciences Ltd (Suven) declared the give of one (1) item patent from India (290964) and one (1) item patent from South Korea (10-1815307) comparing to the New Concoction Elements (NCEs) for the treatment of disarranges related with Neurodegenerative illnesses and these Licenses are substantial through 2029 and 2033 separately.
The conceded cases of the licenses incorporate the class of particular Alpha4 Beta2 and 5-HT4 mixes individually and are being created as remedial specialists for real depressive issue and for the treatment of intellectual hindrance related with neurodegenerative disarranges like Alzheimer’s illness, Consideration
insufficient hyperactivity issue (ADHD), Huntington’s ailment, Narcolepsy, Parkinson and Schizophrenia separately., Organization said in afiling with BSE.
Achieves significant advancement in Cancer Treatment to Enhance Quality of Life As per the National…
-An 11-year-old boy from Yemen and a 34-year-old man from Bengaluru, both suffered from end-stage…
Mumbai, 14th May 2024 – As part of its dedication to exceptional patient care, American Oncology…
Mumbai, May 11, 2024: In a landmark move for Indian healthcare, the introduction of Second…
Bengaluru, May 08, 2024: Cancer remains the illness most feared across the globe. But to combat…
- This specialized division empowers patients with neurological disorders to reclaim their mobility through a…